Publications by authors named "J L Gelpi"
Article Synopsis
- Current SARS-CoV-2 mRNA vaccines are effective, but there's a need for new strategies due to waning immunity and variant emergence, prompting this study on a heterologous mRNA/MVA vaccination approach.
- The research demonstrates that a combination of a trimeric receptor binding domain (RBD) delivered via mRNA and a modified vaccinia virus (MVA) boost creates strong immune responses, including effective antibodies and T cell activity against various SARS-CoV-2 strains.
- The heterologous regimen provided complete protection in specific mouse models after exposure to the virus, outperforming traditional methods and suggesting that alternative nanocarrier technologies could enhance vaccine effectiveness while avoiding patent issues.
Motivation: Software plays a crucial and growing role in research. Unfortunately, the computational component in Life Sciences research is often challenging to reproduce and verify. It could be undocumented, opaque, contain unknown errors that affect the outcome, or be directly unavailable and impossible to use for others.
View Article and Find Full Text PDFInteractive Jupyter Notebooks in combination with Conda environments can be used to generate FAIR (Findable, Accessible, Interoperable and Reusable/Reproducible) biomolecular simulation workflows. The interactive programming code accompanied by documentation and the possibility to inspect intermediate results with versatile graphical charts and data visualization is very helpful, especially in iterative processes, where parameters might be adjusted to a particular system of interest. This work presents a collection of FAIR notebooks covering various areas of the biomolecular simulation field, such as molecular dynamics (MD), protein-ligand docking, molecular checking/modeling, molecular interactions, and free energy perturbations.
View Article and Find Full Text PDFArticle Synopsis
- - Vaccines using mRNA technology, particularly lipid nanoparticles (LNP), are key in combating SARS-CoV-2 and have applications for other diseases too.
- - The study tested various lipid and polymer-based nanoparticles for delivering mRNA that encodes a part of the spike protein from SARS-CoV-2, assessing their toxicity and effectiveness in animal models.
- - Results showed that modified lipid nanoparticles (mLNP) and traditional LNP-1 were highly effective in producing antibodies and protecting mice from COVID-19, suggesting alternative carriers can enhance mRNA vaccine performance.